Systemic therapy for metastatic HER2-positive breast cancer

The human epidermal growth factor receptor 2 (HER2), is amplified and/or overexpressed in approximately 15%–20% of breast cancers. Targeting of the HER2 receptor with the humanized monoclonal antibody trastuzumab in combination with chemotherapy has become the backbone of treatment for both early st...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Seminars in oncology 2020-10, Vol.47 (5), p.259-269
Hauptverfasser:	Bredin, Philip, Walshe, Janice M., Denduluri, Neelima
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - genetics Female HER2 Humans Metastatic breast cancer Receptor, ErbB-2 - genetics Systemic therapy Trastuzumab deruxtecan Trastuzumab emtansine Tucatinib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!